Table 2. Comparison of MDR1/P-gp and MRP-1 co-expression in (a) all melanoma specimens analysed; (b) primary melanoma specimens only; and (c) metastatic melanoma specimens only.
| Drug efflux pump | % Cases |
|---|---|
| (a) | |
| MRP1+and MDR1/P-gp+ | 44.0 (59/134) |
| MRP1− and MDR1/P-gp+ | 13.4 (18/134) |
| MRP1+ and MDR1/P-gp− | 23.1 (31/134) |
| MRP1− and MDR1/P-gp− | 19.4 (26/134) |
| (b) | |
| MRP1+ and MDR1/P-gp+ | 33.7 (31/92) |
| MRP1− and MDR1/P-gp+ | 16.3 (15/92) |
| MRP1+ and MDR1/P-gp− | 22.8 (21/92) |
| MRP1− and MDR1/P-gp − | 27.2 (25/92) |
| (c) | |
| MRP1+ and MDR1/P-gp+ | 66.7 (28/42) |
| MRP1− and MDR1/P-gp+ | 7.1 (3/42) |
| MRP1+ and MDR1/P-gp− | 23.8 (10/42) |
| MRP1− and MDR1/P-gp− | 2.4 (1/42) |
Abbreviations: MDR1/P-gp=multi-drug resistance; MRP=multidrug resistance-associated protein.